Recent Developments for Bavarian Nordic
Bavarian Nordic has recently faced a significant turning point in its corporate history. The takeover offer from Innosera ApS, backed by Nordic Capital and Permira, has been officially withdrawn. This decision comes after the acceptance rate for the offer fell short of the necessary threshold required for completion.
Understanding the Withdrawal of the Offer
On November 6, 2025, Bavarian Nordic reported that the offer period ended without meeting the minimum acceptance condition. The Offeror, Innosera ApS, announced that only 60% of shareholders had accepted the offer, failing to achieve the 66?% required for the bid to proceed. Consequently, the company has decided to retract the offer altogether, rendering all prior acceptances void.
Statements from Leadership
Luc Debruyne, Chair of the Board of Directors at Bavarian Nordic, emphasized the company’s strength and growth potential. He remarked, "We acknowledge and respect the decision made by shareholders, which means that Bavarian Nordic will continue as an independent listed company with its current growth strategy." The board is optimistic about future prospects and committed to enhancing shareholder value moving forward.
Future Engagement with Shareholders
In light of this development, the board and management of Bavarian Nordic see an opportunity to establish a more robust and valuable dialogue with shareholders. They plan to host an informational meeting for shareholders in early December, focusing on critical topics such as the company’s business state, strategic direction, and leadership continuity.
Bavarian Nordic’s Vision and Strategy
Bavarian Nordic is a premier vaccine manufacturer with a mission to improve public health. Their leading position as a supplier for mpox and smallpox vaccines highlights their commitment to public health preparedness. Furthermore, their diverse portfolio of travel vaccines showcases their capability to adapt to global health needs.
Maintaining Strong Market Position
The company’s resilience during this unsettling period demonstrates its robust operational foundation. It remains poised to capitalize on opportunities for innovation and market expansion. As an independent entity, Bavarian Nordic is focused on advancing its strategic initiatives to continue delivering value to stakeholders.
Company Overview
Founded with the goal of delivering innovative vaccines, Bavarian Nordic has positioned itself as a trusted partner for governments and health organizations globally. The company's extensive research and development efforts underscore its commitment to enhancing health outcomes worldwide and managing emerging health threats.
Contact Information for Shareholders
For further inquiries, investors can connect with:
Europe: Disa Tuominen, IR Manager at Bavarian Nordic, can be reached via email at detu@bavarian-nordic.com.
US: Graham Morrell from Gilmartin Group is available at graham@gilmartinir.com, or by phone at +1 781 686 9600.
Frequently Asked Questions
What led to the withdrawal of the takeover offer?
The takeover offer was withdrawn after it received only 60% acceptance from shareholders, failing to meet the required 66?% threshold.
What is Bavarian Nordic's strategy moving forward?
After the withdrawal of the takeover offer, Bavarian Nordic plans to continue executing its growth strategy independently and engage more effectively with shareholders.
How does Bavarian Nordic contribute to public health?
Bavarian Nordic plays a significant role in public health by supplying vaccines for mpox and smallpox, and by offering a range of travel vaccines.
Where can shareholders find more information?
Shareholders can expect an informational meeting in early December, where more details on the company’s status and strategies will be discussed.
How can investors contact Bavarian Nordic?
Investors can reach out to the company through their designated investor relations contacts for further information and inquiries.
